論文 - 詳細
| RRC ID | 57436 |
|---|---|
| 著者 | Saito M, Takano T, Nishimura T, Kohara M, Tsukiyama-Kohara K. |
| タイトル | 3β-hydroxysterol δ24-reductase on the surface of hepatitis C virus-related hepatocellular carcinoma cells can be a target for molecular targeting therapy. |
| ジャーナル | PLoS One |
| Abstract |
In our previous study, we demonstrated that 3β-hydroxysterol Δ24-reductase (DHCR24) was overexpressed in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), and that its expression was induced by HCV. Using a monoclonal antibody against DHCR24 (2-152a MAb), we found that DHCR24 was specifically expressed on the surface of HCC cell lines. Based on these findings, we aimed to establish a novel targeting strategy using 2-152a MAb to treat HCV-related HCC. In the present study, we examined the antitumor activity of 2-152a MAb. In the presence of complement, HCC-derived HuH-7 cells were killed by treatment with 2-152a MAb, which was mediated by complement-dependent cytotoxicity (CDC). In addition, the antigen recognition domain of 2-152a MAb was responsible for the unique anti-HCV activity. These findings demonstrate the feasibility of using 2-152a MAb for antibody therapy against HCV-related HCC. In addition, surface DHCR24 on HCC cells exhibited a functional property, agonist-induced internalization. We showed that 2-152a MAb-mediated binding of a cytotoxic agent (a saponin-conjugated secondary antibody) to surface DHCR24 led to significant cytotoxicity. This suggests that surface DHCR24 on HCC cells can function as a carrier for internalization. Therefore, surface DHCR24 could be a valuable target for HCV-related HCC therapy, and 2-152a MAb appears to be useful for this targeted therapy. |
| 巻・号 | 10(4) |
| ページ | e0124197 |
| 公開日 | 2015-1-1 |
| DOI | 10.1371/journal.pone.0124197 |
| PII | PONE-D-14-57568 |
| PMID | 25875901 |
| PMC | PMC4395381 |
| MeSH | Antibodies, Monoclonal / pharmacology* Blotting, Western Carcinoma, Hepatocellular / drug therapy* Carcinoma, Hepatocellular / enzymology Carcinoma, Hepatocellular / etiology Cell Proliferation Enzyme-Linked Immunosorbent Assay Flow Cytometry Hepacivirus / physiology* Hepatitis C, Chronic / complications* Hepatitis C, Chronic / enzymology Hepatitis C, Chronic / virology Humans Liver Neoplasms / drug therapy* Liver Neoplasms / enzymology Liver Neoplasms / etiology Molecular Targeted Therapy Nerve Tissue Proteins / antagonists & inhibitors* Nerve Tissue Proteins / immunology Nerve Tissue Proteins / metabolism Oxidoreductases Acting on CH-CH Group Donors / antagonists & inhibitors* Oxidoreductases Acting on CH-CH Group Donors / immunology Oxidoreductases Acting on CH-CH Group Donors / metabolism Tumor Cells, Cultured Virus Replication / drug effects* |
| IF | 2.776 |
| 引用数 | 4 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 12 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| 遺伝子材料 | pCAG-HIVgp (RDB04394) pCMV-VSV-G-RSV-Rev (RDB04393) |